Anti-Venom Market, by Anti-Venom Type (Polyvalent, Monovalent), by Product Type (Snake Anti-venom, Scorpion Anti-venom, Spider Anti-venom, Other Anti-venom product), by Distribution Channel (Hospitals, Private Clinics, Ambulatory Surgical Centers) - Globa

Anti-Venom Market, by Anti-Venom Type (Polyvalent, Monovalent), by Product Type (Snake Anti-venom, Scorpion Anti-venom, Spider Anti-venom, Other Anti-venom product), by Distribution Channel (Hospitals, Private Clinics, Ambulatory Surgical Centers) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022 - 2028

Anti-venom is a medication majorly used to treat snake bites and it can also be used to treat bites from scorpions, spiders or other reptiles. It is made by fractionating the blood of the donor (horse or sheep), which is hyper immunized with snake venom. These products are available in either lyophilized or liquid forms. Anti-venom is the only effective therapy against snake bites and they also save patients from cell and tissue necrosis, thus helping save vital organs.
Market Dynamics
The incidence of animal bite such as snake, and scorpion is high. High incidence of poisonous animal bite is also expected to be a major factor driving demand for anti-venom in the near future.
For instance, according to the data published by World Health Organization (WHO), in 2018, it was estimated that globally, the incidence of snakebite is around 4.5 to 5.4 million bites from venomous and non-venomous snakes, out of which around 1.8 million to 2.7 million cases of snakebite are envenoming.
Increasing initiatives by government and various other organizations to increase awareness about snake bite and its treatment is further expected to support adoption of anti-venoms during forecast period. For instance, World Health Organization (WHO), in June 2021, added snakebite to its priority list of neglected tropical disease, which would result in more focused effort to prevent death from snakebite, thus boosting growth of the anti-venom market.
Key features of the study:
This report provides in-depth analysis of anti-venom market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global anti-venom market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include BTG plc. Laboratorios Silanes, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., and Rare Disease Therapeutics Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global anti-venom market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the anti-venom market
Detailed Segmentation:
Global Anti-venom Market, By Animal Type :
Snake
Scorpion
Spider
Others
Global Anti-venom Market, By Anti-venom Type:
Monovalent
Polyvalent
Global Anti-venom market, By Distribution Channel:
Hospital
Retail Pharmacies
Others
Global Anti-venom Market, By Geography:
North America
By Animal Type :
Snake
Scorpion
Spider
Others
By Anti-venom Type:
Monovalent
Polyvalent
By Distribution Channel
Hospital
Retail Pharmacies
Others
By Country:
U.S.
Canada
Europe
By Animal Type :
Snake
Scorpion
Spider
Others
By Anti-venom Type:
Monovalent
Polyvalent
By Distribution Channel
Hospital
Retail Pharmacies
Others
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Animal Type :
Snake
Scorpion
Spider
Others
By Anti-venom Type:
Monovalent
Polyvalent
By Distribution Channel
Hospital
Retail Pharmacies
Others
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Animal Type :
Snake
Scorpion
Spider
Others
By Anti-venom Type:
Monovalent
Polyvalent
By Distribution Channel
Hospital
Retail Pharmacies
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Animal Type :
Snake
Scorpion
Spider
Others
By Anti-venom Type:
Monovalent
Polyvalent
By Distribution Channel
Hospital
Retail Pharmacies
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Animal Type :
Snake
Scorpion
Spider
Others
By Anti-venom Type:
Monovalent
Polyvalent
By Distribution Channel
Hospital
Retail Pharmacies
Others
By Country:
Central Africa
South Africa
North Africa
Company Profiles
BTG plc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Laboratorios Silanes
CSL Limited
Pfizer, Inc.
Merck & Co., Inc.
Bharat Serums and Vaccines Limited
Haffkine Bio-Pharmaceutical Corporation Ltd.
Vins Bioproducts Limited
Incepta Pharmaceuticals Ltd.
Rare Disease Therapeutics Inc.
“*” marked represents similar segmentation in other categories in the respective section.